The FDA’s expanded access pathway allows patients with no other therapeutic options to request access to investigational agents, but manufacturers do not often grant it.
AMA J Ethics. 2015;17(12):1142-1146. doi:
10.1001/journalofethics.2015.17.12.stas1-1512.
The NRMP’s new “all-in” policy requires every residency program to fill every first-year position either exclusively through the match or outside of it. Programs that continue to offer prematches will operate outside the match.
Nisha Quasba joins Ethics Talk to discuss her article, coauthored with Elliot Vice: “What Should Prescribers and Policy Makers Know About US Drug Importation?”
Dr Amy B. Cadwallader joins Ethics Talk to discuss her article, coauthored with Kavitha Nallathambi: “How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?”